Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
2.620
+0.120 (4.80%)
Sep 2, 2026, 4:00 PM EDT - Market closed
Serina Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 23.02 | 3.06 | 3.67 | 7.62 | 0.53 | 0.31 |
Short-Term Investments | - | - | - | - | - | 1 |
Cash & Short-Term Investments | 23.02 | 3.06 | 3.67 | 7.62 | 0.53 | 1.31 |
Cash Growth | 281.13% | -16.78% | -51.80% | 1331.53% | -59.41% | - |
Receivables | - | - | - | - | - | 0 |
Prepaid Expenses | 2.01 | 0.99 | 1.93 | - | 0.02 | 0.02 |
Other Current Assets | - | 2.03 | 0.08 | - | - | - |
Total Current Assets | 25.03 | 6.08 | 5.68 | 7.62 | 0.55 | 1.33 |
Property, Plant & Equipment | 0.76 | 0.84 | 1.05 | 1.35 | 0.31 | 0.51 |
Other Long-Term Assets | 0.03 | 0.03 | - | - | - | - |
Total Assets | 25.81 | 6.95 | 6.72 | 8.97 | 0.86 | 1.84 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.86 | 1.93 | 0.74 | 0.58 | 0.14 | 0.15 |
Accrued Expenses | 1.36 | 1.21 | 1.43 | 0.58 | 0.01 | 0.01 |
Current Portion of Leases | 0.55 | 0.18 | - | 0.25 | 0.13 | 0.21 |
Current Unearned Revenue | - | - | - | - | 0.15 | - |
Other Current Liabilities | - | 0.24 | 0.19 | - | 0.01 | 0 |
Total Current Liabilities | 3.76 | 3.56 | 2.37 | 1.41 | 0.44 | 0.37 |
Long-Term Debt | 3.09 | 2.95 | - | 2.98 | 1.62 | - |
Long-Term Leases | 0.12 | 0.2 | 0.27 | 0.46 | 0.06 | 0.19 |
Other Long-Term Liabilities | 0.11 | 0.28 | 3.58 | - | 1.08 | 0.95 |
Total Liabilities | 7.08 | 6.99 | 6.22 | 4.86 | 3.19 | 1.51 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | - | 0.02 | 0.02 |
Additional Paid-In Capital | 95.48 | 58.54 | 44.96 | 0.88 | 0.65 | 0.64 |
Retained Earnings | -76.75 | -63.5 | -44.32 | -33.18 | -38.45 | -35.76 |
Comprehensive Income & Other | - | -0.01 | - | - | - | - |
Total Common Equity | 18.73 | -4.98 | 0.64 | -32.29 | -37.78 | -35.11 |
Minority Interest | - | - | -0.13 | - | - | - |
Shareholders' Equity | 18.73 | -0.04 | 0.51 | 4.11 | -2.34 | 0.33 |
Total Liabilities & Equity | 25.81 | 6.95 | 6.72 | 8.97 | 0.86 | 1.84 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.75 | 3.32 | 0.27 | 3.7 | 1.81 | 0.4 |
Net Cash (Debt) | 19.27 | -0.27 | 3.4 | 3.92 | -1.28 | 0.91 |
Net Cash Growth | 239.32% | - | -13.25% | - | - | - |
Net Cash Per Share | 1.56 | -0.03 | 0.46 | 0.53 | -0.60 | 0.43 |
Filing Date Shares Outstanding | 25.4 | 12.31 | 9.93 | 8.79 | 2.22 | 2.14 |
Total Common Shares Outstanding | 25.4 | 10.77 | 9.42 | 2.47 | 2.22 | 2.14 |
Working Capital | 21.27 | 2.52 | 3.31 | 6.21 | 0.11 | 0.96 |
Book Value Per Share | 0.74 | -0.46 | 0.07 | -13.09 | -17.03 | -16.37 |
Tangible Book Value | 18.73 | -4.98 | 0.64 | -32.29 | -37.78 | -35.11 |
Tangible Book Value Per Share | 0.74 | -0.46 | 0.07 | -13.09 | -17.03 | -16.37 |
Machinery | - | 0.88 | 0.97 | 0.87 | 0.38 | 0.37 |